March 10, 2026 Flerie’s portfolio company Lipum selected for EUR 8 million Horizon Europe grant Read more
February 27, 2026 Flerie’s portfolio company Xspray Pharma appoints Blake Leitch as CEO and resubmits application for market approval of Dasynoc® to the FDA Read more
February 11, 2026 Flerie’s portfolio company Microbiotica reports positive Phase 1b data for MB310 in patients with ulcerative colitis Read more
January 20, 2026 Flerie’s portfolio company Chromafora acquires Montrose Environmental Group Denmark Read more
January 9, 2026 Flerie’s portfolio company KAHR Bio presents strong survival data from Phase II trial with DSP107 and secures USD 22 million in equity funding Read more
November 4, 2025 Flerie’s portfolio company Empros Pharma reports study results positioning EMP16 as a promising oral weight-loss maintenance therapy Read more
October 8, 2025 Flerie’s portfolio company Xspray Pharma provides update on FDA process for Dasynoc®; observations at contract manufacturer delay approval Read more
September 23, 2025 Flerie’s portfolio company Xintela has presented positive 24-month data for its stem cell product XSTEM Read more
September 11, 2025 Flerie’s portfolio company Xspray Pharma has raised SEK 161 million in oversubscribed rights issue Read more
June 3, 2025 Flerie’s portfolio company KAHR Bio presents positive results from its Phase II trial with DSP107 in combination with anti-PD-L1 in colorectal cancer Read more
May 14, 2025 Flerie’s portfolio company NorthX Biologics secures growth investment from Signet Healthcare Partners Read more
April 25, 2025 Flerie’s portfolio company Xintela signs global collaboration and license agreement with EQGen Biomedical Read more
April 24, 2025 Flerie’s portfolio company Nanologica has received an important order from a new customer Read more
April 14, 2025 Flerie’s portfolio company Lipum presents positive results from its Phase I trial with SOL-116 Read more
April 4, 2025 Data supporting the use of Mendus’ DCOne platform to improve production of ovarian cancer TIL therapies presented at ITOC conference Read more
March 18, 2025 Xintela’s stem cell product XSTEM shows safety and positive efficacy results in knee osteoarthritis clinical study Read more
